Takeda Pays Big For De-Risked HutchMed CRC Drug
Executive Summary
The Japanese pharma agreed to pay $400m up front plus up to $730m in milestones for a colorectal cancer drug already on the market in China and nearing regulatory filings in the US, EU and Japan.
You may also be interested in...
Takeda On Continued Lookout For Assets After Recent Deals
Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.